Brian A. Silikovitz Partner

New York Roseland
T 646.414.6888 | F 973.597.2563

Chair, Tax Practice

Brian A. Silikovitz is Chair of the Firm's Tax practice. He provides structuring and other tax advice in mergers and acquisitions, fund formation, debt and equity investments, executive compensation, and other tax issues that arise throughout the life of a business.

Brian works extensively with Lowenstein Sandler’s Tech Group, advising start-ups on initial choice of business entity and structuring of early-stage investments. His counsel takes into account such factors as the likely operational results in early years, incentive compensation issues, and tax issues that likely will arise upon venture capital financings and ultimately in exit transactions. He also works closely with the firm’s Investment Management Group, advising on the structure of hedge funds and private equity funds and their management entities, considering the special needs of tax-exempt and foreign investors and the managers of those funds.

Brian takes particular pride in his practical, results-oriented approach, helping clients not only with the substance of their tax issues but also with the economic impact of those issues on their businesses. He avoids jargon and explains issues in understandable terms so that decision makers can act quickly and knowledgeably.

Brian is a member of the Recruiting Committee and serves as a program coordinator for the firm’s summer associate program. He especially enjoys getting to know the summer associates personally and helping introduce them to life at the firm.

Brian also is an Adjunct Professor at the Rutgers School of Law.

Representative Engagements

Regularly provides advice on the tax aspects of mergers and acquisitions—including structuring for particular goals such as tax-free receipt of buyer equity, step-up in asset basis, and efficient use of net operating losses and other tax attributes—and on drafting and negotiating tax indemnity and related provisions of transaction documents.
Prepares the economic and tax provisions of complex partnership and limited liability company operating agreements.
Represents clients on state and local tax issues, including the often uncertain sales and use tax issues arising from "SaaS" businesses and e-commerce in general.
View More...


Year-End Developments and Compliance Checklists
Investment Management Client Alert, January 22, 2015
Scott Moss, George Danenhauer, Andrew Graw, Matthew Magidson, Brian Silikovitz, Jonathan Wishnia, Lesley Adamo, Christina Iafe, Joanna Miller-Suna
How Startup Founder Stock Often Triggers Unnecessary Personal Tax Hits
Forbes, January 6, 2015
Brian Silikovitz, Ed Zimmerman
FATCA – Important Implementation Updates
Tax Client Alert, April 9, 2014
Brian Silikovitz, Lesley Adamo
View More...

Press Mentions

Lowenstein Sandler is representing Covis Pharma S.á.r.l and Covis Injectables S.á.r.l, global specialty pharmaceutical companies providing therapeutic solutions to patients, in connection with the announcement of their all-cash $1.2 billion sale of assets to Concordia Healthcare Corp (TSX: CXR), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The acquisition is expected to close in the second quarter of 2015. The Lowenstein deal team was led by Ethan A. Skerry, Robert G. MinionPeter H. Ehrenberg and also included Nicholas G. Mehler, Sam E. Khan, Katie Cobb, Brian Shemesh, Jack D. Sidorov, Jeffrey M. Shapiro, Hilla Shimshoni, Lowell A. Citron, Theodore C. Sica, Brian A. Silikovitz, Christina IafeJean N. Samedi and Brandon Greenblatt. , March 10, 2015
Lowenstein Sandler represented Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, in connection with its licensing of a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ:AMGN). Financial terms of the agreements were not disclosed. Celimmune plans to initiate Phase 2 studies of AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease (RCD). Celiac disease is a chronic hereditary systemic autoimmune and inflammatory disease triggered by gluten consumption. The Lowenstein team included Michael J. Lerner, Herschel Weinstein, Park S. Bramhall, Brian A. Silikovitz and Lesley P. Adamo. , March 2, 2015
Lowenstein Sandler is representing SilverSky, the leading independent provider of cloud-based security software and managed services, in its acquisition by BAE Systems plc, a British multinational defense, security and aerospace company headquartered in London. The transaction was announced on October 21, 2014. The Lowenstein team includes Anthony O. Pergola, David B. Haber, Brian A. Silikovitz, Andrew E. Graw, Alex D. Leibowitz, Jamie Kapalko, and Darren S. Goodman. , October 21, 2014
View More...

Related Areas

Corporate Finance & Securities
Employee Benefits & Executive Compensation
Investment Management
Life Sciences
Mergers & Acquisitions
Mortgage & Structured Finance
The Tech Group
Venture Capital, Angel Investing, and M&A


New York University School of Law ( LL.M. , 1997 ) , Taxation
University of Southern California Law Center ( J.D. , 1992 ) , Notes Editor, Southern California Law Review
University of Pennsylvania ( B.A. , 1989 )

Bar Admissions

New York
New Jersey


  • Adjunct Professor, Rutgers School of Law 
  • University of Pennsylvania Alumni Interview Program 
  • New York State Bar Association Tax Section